P-MAPS II – Pancreatitis – Microbiome as Predictor of Severity
Research type
Research Study
Full title
P-MAPS II – Pancreatitis – Microbiome as Predictor of Severity
IRAS ID
346039
Contact name
Sanjay Pandanaboyana
Contact email
Sponsor organisation
Newcastle upon Tyne Hospital
Duration of Study in the UK
1 years, 6 months, 13 days
Research summary
This is a multi centre study which is the lead site is University Medical Center l Goettingen, Germany.
Background and rationale:
Despite intensive research, early prediction of the course of acute pancreatitis (AP) is still not satisfactorily possible . Our results of a European multicenter study showed that the intestinal microbiome is superior to established scores as a marker of severity in patients with AP. A classifier was created using 16 differentially abundant rectal species and systemic inflammatory response syndrome (SIRS) and achieved an AUROC of 85%. Surprisingly, all species in the severe AP group were members of taxonomic families known for their short-
chain fatty acid (SFCA) production. This observation contrasts with translational pancreatitis studies in mice. Based on these publications, a clinical trial is currently being initiated to treat severe AP with SCFAHowever, previous well-designed RCT that analyzed the effects of probiotics in predicted severe AP resulted in a worse outcome for patients in the probiotic arm . Consequently, national and international guidelines recommend against the usage of probiotics in AP .
Collectively, more research is needed to further elucidate the role of the oro-intestinal microbiota in the development of severe AP. To validate the results of our multicenter study and to profoundly analyze the role of microbial metabolites and the fungeome, we plan to recruit patients with AP prospectively.REC name
West Midlands - Solihull Research Ethics Committee
REC reference
24/WM/0169
Date of REC Opinion
12 Aug 2024
REC opinion
Further Information Favourable Opinion